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Background. Acute liver failure can result from acetaminophen overdose, viral infection, toxins, and other disease conditions. Liver
transplant is available in limited fashion and the criteria are strict as to who should get an available liver. N- Acetyl Cysteine
(NAC) has been used in non-acetaminophen induced liver failure with success. Here we report a case of acute liver failure from
cocaethylene that was reversed with NAC along with other medical therapy. Case Presentation. A 50-year-old female patient
presented to the Emergency Department (ED) with a two-day history of coffee ground vomiting and hematemesis. She reported
occasional substance abuse and heavy alcoholism. She reported shortness of breath and chest pain from the recurrent forceful
vomiting. The rest of the review of systems was unremarkable except a fall from intoxication. Physical examination revealed anicteric
conjunctiva and nontender abdomen and her vital signs were within normal limits. Initial blood work revealed acute liver and
renal failure. The patient was started with general medical management and liver transplant service rejected the case due to active
substance abuse. She underwent brief hemodialysis and was started on NAC. Over the course of her hospital stay her liver function
and kidney function improved significantly and patient was discharged to home. Conclusion. In cases where liver transplant is
not an option for various reasons including active substance abuse, a trial of N-Acetyl Cysteine may be beneficial and should be
considered in the Emergency Department.

1. Introduction

2. Narrative

Acute liver failure can result from acetaminophen overdose,
viral infection, toxins, and other disease conditions [1–3].
Liver transplant is available in limited fashion and the criteria
are strict as to who should get an available liver. In case of
acetaminophen induced acute liver failure N-Acetyl Cysteine
(NAC) has been used with success [4]. Some case reports
indicated that this treatment has also showed promising
results in non-acetaminophen induced liver failure [5, 6].
Here we report a case of acute liver failure from cocaethylene (with concomitant use of alcohol and cocaine) that
was reversed with NAC alongside general medical therapy,
including emergent hemodialysis.

A 50-year-old female patient presented to the Emergency
Department (ED) with a two-day history of coffee ground
vomiting and hematemesis. She had not been able to hold
down food and was not eating much. She reported occasional
cocaine abuse and heavy alcoholism. She also reported
shortness of breath and chest pain from the recurrent forceful
vomiting and constipation. The rest of the review of systems
was unremarkable, other than a fall from intoxication. Physical examination revealed: blood pressure of 147/77 mmHg,
respiratory rate of 18 breath per minute, pulse rate of 115 beats
per minute, temperature of 97 degree Fahrenheit, and oxygen
saturation of 100% on room air. She appeared pale and had
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anicteric bilateral temporal subconjunctival hemorrhage and
a nontender abdomen. The rest of the physical examination
was unremarkable.
Initial blood work revealed a hemoglobin/hematocrit
(H/H) of 11.2mg/dL/36.2%, glucose of 35mg/dL, bicarbonate of 7 mmol/mL, and creatinine of 3.1mg/dL with an
anion gap of 44. Her liver function test revealed aspartate
aminotransferase (AST) 18487U/L, alanine aminotransferase
(ALT) 6015U/L, alkaline phosphatase (ALK P) 229U/L, total
bilirubin 2.499mg/dL, direct bilirubin 2.18mg/dL, albumin
3.3g/dL, lactate 27 mmol/L, a blood alcohol level of 36 mg/dL,
and urine toxicology positive for cocaine. International
Normalized Ration (INR) was 3.01 and pH was 7.06. Her
acetaminophen level was 5.8mg/dL (normal range: 10-30) and
the salicylate level was 3.7mg/dL (normal range: 2.8-20).
Her Model for End-Stage Liver Disease (MELD) score
was 19 predicting a 3-month mortality of 6%. The patient was
started with dextrose of 50%, protein pump inhibitor with
medical intensive care unit (MICU), and gastrointestinal (GI)
consultation. She received a PRBC transfusion along with
octreotide. Liver transplant service rejected the case due to
active substance abuse and, as per GI recommendation, she
was started on N-Acetyl Cysteine (NAC).
An extensive work up revealed the following: Hepatitis B, C, and E were nonreactive, thyroid function was
within normal limit, with slightly low complement factors
3 and 4, normal myeloperoxidase antibody, normal copper
level, slightly elevated CA19, and Alpha Fetoprotein (AFP).
Proteinase-3 A and Alpha 1 Antitrypsin negative were negative, and Ceruloplasmin was slightly decreased. The patient
had slightly elevated iron level, slightly decreased Tissue
Iron Binding Capacity (TIBC), and transferrin saturation
of 76%. Tests for mitochondrial antibody, smooth muscle
antibody negative, and liver kidney microsomal antibody
were negative, and there was low Factor V level. Normal
antinuclear and Anti-Streptolysin antibody were normal. No
assay was performed to detect cocaethylene as it is not a
routine test.
The patient received general medical stabilization and
treatment, including brief hemodialysis and treatment with
NAC over the course of her hospital stay, and experienced
significant improvement and near resolution of both liver and
renal function abnormalities. At discharge her laboratory values were as follows: AST 64 U/L, ALT 216 U/L, ALP 142 U/L,
creatinine 1.7mg/dL, total bilirubin 1.23mmol/L, direct bilirubin 0.79mmol/L, INR 1.26, H/H 11.5mg/dL/35.6%, ammonia
25Umol/L, and lactate 1.8mmol/L.
The patient was discharged to her home in improved
condition and advised to follow up in the outpatient clinic
with counseling for alcohol and substance abuse.

3. Discussion
Acetaminophen is the major cause of acute liver failure,
but other factors such as viral infection, chronic alcohol
abuse, and other toxins and drugs, as well as some medical
conditions, lead to liver failure [1–3, 7, 8]. A combination of
any of the abovementioned causes poses a greater risk for liver
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damage. The toxic effects of the cocaine-alcohol combination
have been observed both in Emergency Department (ED)
and in inpatient medical units. Ethanol alters the hepatic
biotransformation of cocaine, resulting in a novel active
metabolite, cocaethylene [9–11]. Oral cocaine was suggested
to produce relatively larger concentrations of cocaethylene
[12–15]. Drug abusers combine cocaine and alcohol to get
intense high and less paranoia when coming off the high
[16–18]. Both alcohol and cocaine cause liver toxicity, but
cocaethylene appears to be more potent in its toxicity than
cocaine [19–22].
Of the various mechanisms of N-Acetyl-P Aminophenol (APAP), acetaminophen, and metabolism approximately
5% to 10% are metabolized by cytochrome P450 system
to N-acetyl-p-benzoquinoneimine (NAPQI) [23], a highly
reactive molecule that damages hepatocytes by formation
of covalent bonds with other intracellular proteins. This
reaction is prevented by conjugation with glutathione and
subsequent reactions to generate a water-soluble product [24,
25]. Overdose acetaminophen is increasingly metabolized
by cytochrome P450 generating NAPQI in amounts that
can deplete glutathione. With glutathione depletion and not
being replenished faster, NAPQI will begin to accumulate in
the hepatocytes resulting in direct hepatocyte damage [3].
Glutathione is important in preventing the accumulation
of peroxides and superoxide radicals and is reduced from
70% to 80% in cases of acetaminophen induced liver cell
toxicity [26]. There is approximately 20%-40% reduction in
glutathione with cocaine-induced liver cell necrosis [27, 28].
On the contrary, overnight fasting causes a 50% reduction
in glutathione without associated liver cell damage [29]
and glutathione decrease in itself does not explain covalent
binding of metabolically active cocaine metabolites to hepatic
proteins [30]. These factors imply that there must be other
reasons for liver toxicity other than glutathione depletion. Nacetyl cysteine (NAC), a precursor of glutathione, is an effective antidote for APAP poisoning. When administered early
after an acute APAP overdose, NAC provides cysteine for
the replenishment and maintenance of hepatic glutathione
stores, enhances the sulfation pathway of elimination, and
may directly reduce NAPQI back to acetaminophen [31, 32].
Some work showed improved transplant-free survival in
patients with APAP-induced fulminant liver failure (FHF)
[33, 34]. The mechanism here is not the detoxification
of NAPQI but rather enhanced recovery. Several different
mechanisms seem to contribute to the efficacy of NAC in
this setting. NAC improves hepatic perfusion and oxygen
delivery and extraction in patients with APAP-induced FHF
[35]. Other beneficial effects include scavenging of reactive
oxygen and nitrogen species and improved mitochondrial
energy production [36, 37]. These beneficial effects of NAC
do not seem to be unique to APAP hepatotoxicity [5].
The mechanisms by which cocaine causes liver cell injury
appear to be similar to that of liver injury caused by the
toxic metabolite of acetaminophen. It is related to production of highly reactive metabolites, with peroxidation, free
radical formation, and covalent binding to hepatic proteins.
Approximately 10% of cocaine undergoes N-demethylation
in hepatocytes by the cytochrome P-450-mixed function
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oxidase system, forming norcocaine, a metabolite that elicits
significant liver cell damage when injected intraperitoneally
in mice [13–15]. This is due to further enzymatic breakdown to N-hydroxynorcocaine and norcocaine nitroxide
[38]. Oxidation to the nitrosonium ion showed the latter to
be highly reactive with glutathione, serving as catalyst for
the conversion of alcohols, amines, and hydroxide ions to
aldehydes, ketones, and hydrogen peroxide and causing lipid
peroxidation of cell membranes [12, 39–41].
Patients with acute liver failure (ALF) could deteriorate
rapidly, and although a minority of patients may recover, the
majority require liver transplantation as a life-saving therapy.
Patients need to be immediately recognized, optimizing treatment started, and centers for liver transplantation contacted
to facilitate the process. Before the era of transplantation, the
mortality rate from ALF was greater than 80% [42]. Survival
rates have improved significantly with better understanding
of the clinical syndrome, earlier recognition, intensive care
monitoring, and transplantation [43].
Compared to patients with acetaminophen induced ALF,
patient with non-acetaminophen induced ALF have a spontaneous survival rate of 30%. Patients with non-acetaminophen
toxicity have limited therapeutic options and the majority of
them require transplantation [43, 44]. Unfortunately, there
are strict criteria to qualify for liver transplantation and
active substance abuse makes a candidate less fit to get
transplant. Given the limited therapeutic options and the
graveness of the disease, attempt have been made to treat
patients with non-acetaminophen ALF using NAC. Few
case reports have shown promising results, especially when
applied early on in patents with lower coma grades [6, 45–47].
The first prospective, double-blinded, randomized control
study with NAC in non-acetaminophen induced liver failure
showed a significant improvement in patients with lowergrade encephalopathy. The transplant-free survival for NAC
group was higher (40%) than those without NAC (27%) [5].
In summary, even though both alcohol and cocaine can
lead to liver toxicity, the acute liver failure is presumed to
be from the potent effect of cocaethylen even if no assay
was performed to quantify the cocaethylene level. A potential
toxic agent is acetaminophen, but with no toxic blood level
it is less likely to be the cause of the acute liver failure. Nacetylcysteine offers potential and early treatment options
for patients with ALF from non-acetaminophen causes to
improve liver function rapidly and in severe cases until
transplantation is available .

4. Conclusion
Liver failure is the result of multiple pathological conditions,
toxin effects, and viral infection. N-acetylcysteine has been
predominantly used for acetaminophen induced liver failure, in some instance, in non-acetaminophen induced liver
failure, but it has also had some success in some instance
of non-acetaminophen induced liver failure. In cases where
liver transplant is not an option for various reasons, including
active substance abuse as in this patient’s case, a trial of NAC
may be beneficial.
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